NeuroScientific (ASX:NSB) Secures StemSmart Technology, Charts Fresh Clinical Path

June 27, 2025 01:19 PM AEST | By Team Kalkine Media

NeuroScientific (ASX:NSB) Secures StemSmart Technology, Charts Fresh Clinical Path — Image source: Shutterstock

Strategic Board Transition

With the acquisition in place, NSB also announced key leadership transitions to align with its updated strategic focus. Robert McKenzie has been appointed as Non-Executive Chairman, and Paul Fry joins as Non-Executive Director. Both appointments took effect on 27 June 2025. Each has received 5 million unquoted options, exercisable at $0.07. Paul Fry will also undertake a consultancy role to assist during this transitional period. Departing directors include Tony Keating and Christopher Ntoumenopoulos, who have stepped down from their respective executive roles.

Clinical Expansion Focused on Crohn’s Disease

NSB is accelerating its clinical pathway with the launch of a Special Access Scheme (SAS) for treating fistulising Crohn’s disease—a condition known for its complexity and limited therapeutic outcomes. StemSmart™ Mesenchymal Stem Cell (MSC) therapy has shown encouraging early-phase results, demonstrating potential in both safety and clinical efficacy. The majority of participants in the Phase 2 trial exhibited either improvement or remission, marking an important milestone in NSB’s pursuit of next-generation treatment modalities.

The company aims to eventually advance these therapies toward regulatory approval, building a long-term vision for wider patient accessibility. While NSB is not currently part of the ASX 200, its growing innovation pipeline and financial backing position it among promising players in the biotech sector.

A Forward-Looking Milestone

This acquisition and leadership refresh signals a forward-looking phase for NeuroScientific (NSB). The focus on delivering viable alternatives for chronic inflammatory diseases through stem cell innovation may open new clinical possibilities and partnerships in the biotech landscape. As the company pivots from research to patient-facing access programs, the emphasis on efficacy and sustained recovery may resonate strongly within both the clinical community and market stakeholders.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.